Profile image
Story Views

Last Hour:
Last 24 Hours:

Multiple Myeloma Drugs Market 2017 Global Analysis and Forecast to 2021

Thursday, February 23, 2017 23:47
% of readers think this story is Fact. Add your two cents.

The analysts forecast the global multiple myeloma drugs market to grow at a CAGR of 9.19% during the period 2017-2021.

Multiple myeloma is an abnormal growth and accumulation of plasma cells in the bone marrow leading to malignancy. This can be caused by the overproduction of monoclonal immunoglobulins such as IgG, IgA, IgD, or IgE; or Bence-Jones protein. Under normal conditions, stem cells develop into B lymphocytes, mature in the lymph nodes, and are transported throughout the body. On the entry of foreign substances into the body, these B-cells develop into plasma cells and produce immunoglobulins against the disease. However, in multiple myeloma, the B-cells are damaged and give rise to many malignant plasma cells that produce excessive immunoglobulins of a single type, which the body does not require.

Download Sample Report @

Covered in this report

The report covers the present scenario and the growth prospects of the global multiple myeloma drugs market for 2017-2021. To calculate the market size, the report considers the revenue generated from the sales of branded and generic drugs used to treat and prevent multiple myeloma.

The market is divided into the following segments based on geography:
• Americas

The report, Global Multiple Myeloma Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
• Amgen
• Celgene
• Johnson & Johnson
• Novartis
• Takeda Pharmaceuticals

Other prominent vendors
• AB Science
• AbbVie
• Acceleron Pharma
• Acetylon Pharmaceuticals
• Adaptimmune Therapeutics
• Alexion Pharmaceuticals
• AmpliMed Corporation
• Array BioPharma
• Benovus Bio
• BioInvent
• Biokine Therapeutics
• Biotest
• bluebird bio
• Bristol-Meyer Squibb
• Calithera Biosciences
• CASI Pharmaceuticals
• Celldex Therapeutics
• Cellectar Biosciences
• Chroma Therapeutics
• Cleave Biosciences
• Curis
• Dicerna Pharmaceuticals
• Eureka Therapeutics
• F. Hoffmann-La Roche
• Geron Corporation
• GlycoMimetics
• GlaxoSmithKline
• ImmunoGen
• Immunomedics
• Innate Pharma
• JW Pharmaceutical
• Karyopharm Therapeutics
• Kyowa Hakko Kirin
• Merck
• Midatech Pharma
• Mirna Therapeutics
• Molecular Partners
• MorphoSys
• NOXXON Pharma
• Oncoceutics
• Oncolytics Biotech
• OncoPep
• Oncopeptides
• Ono Pharmaceutical
• Otsuka Pharmaceuticals
• Patrys
• PharmaMar
• Polyphor
• Prothena Therapeutics
• Sanofi
• Sevion Therapeutics
• Specialised Therapeutics
• Spectrum Pharmaceutical
• SymBio Pharmaceuticals
• TaiGen Biotechnology
• Tragara Pharmaceuticals
• Vaxil Therapeutics
• Vivolux

Market driver
• Growing demand for biologic therapies
• For a full, detailed list, view our report

Market challenge
• Growing popularity of complementary and alternative medicines (CAM)
• For a full, detailed list, view our report

To Get More Details For The Reports:

Market trend
• Emergence of nanomedicine platform
• For a full, detailed list, view our report

Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?

Table Of Contents – Major Key Points

PART 01: Executive summary
PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Disease overview
• Understanding the disease

PART 06: Pipeline analysis
PART 07: Market landscape
• Global multiple myeloma drugs market
• Five forces analysis

PART 08: Market segmentation by therapy
• Targeted therapy
• Biologic therapy
• Chemotherapy
• Others

PART 09: Geographical segmentation
• Multiple myeloma drugs market in Americas
• Multiple myeloma drugs market in EMEA
• Multiple myeloma drugs market in APAC

PART 10: Market drivers
• Growing demand for biologic therapies
• Paradigm shift toward the adoption of novel proteasome inhibitors
• Presence of large patient pool

PART 11: Impact of drivers
PART 12: Market challenges
• Growing popularity of complementary and alternative medicines (CAM)
• High costs affecting the adoption rates of multiple myeloma drugs
• Adverse effects of drugs


Check Discount On This Report @

For more information, please visit

For more information content with us;

Sam Collins

Market Reports Center 1-646-883-3044 (US)


We encourage you to Share our Reports, Analyses, Breaking News and Videos. Simply Click your Favorite Social Media Button and Share.

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Top Global


Top Alternative




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.